← All trials
NCT04711109
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Jul 31, 2027
- Completion date
- Dec 31, 2033
- First posted
- Jan 15, 2021
- Last posted
- Jul 20, 2021
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- National Cancer Institute (NCI)Collaborator
- Harvard UniversityStudy chair
- Austrian Breast and Colorectal Cancer GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.